BACKGROUND AND PURPOSE: The ω-3 polyunsaturated fatty acids (PUFAs) mediate protective effects on several metabolic disorders. However, the functions of their metabolites in the early stage of nonalcoholic fatty liver disease (NAFLD) are largely unknown. EXPERIMENTAL APPROACH: Mice were fed a control diet, high-fat diet (HFD) or ω-3 PUFA-enriched HFD (ω3HFD) for 4 days and phenotypes were analysed. LC-MS/MS was used to determine the eicosanoid profiles. Primary hepatocytes and peritoneal macrophages were used for the mechanism study. KEY RESULTS: In short-term HFD-fed mice, the significantly increased lipid accumulation in the liver was reversed by ω-3 PUFA supplementation. Metabolomics showed that the plasma concentrations of hydroxyeicosapentaenoic acids (HEPEs) and epoxyeicosatetraenoic acids (EEQs) were reduced by a short-term HFD and markedly increased by the ω3HFD. However, HEPE/EEQ treatment had no direct protective effect on hepatocytes. ω3HFD also significantly attenuated HFD-induced adipose tissue inflammation. Furthermore, the expression of pro-inflammatory cytokines and activation of the JNK pathway induced by palmitate were suppressed by HEPEs and EEQs in macrophages. 17,18-EEQ, 5-HEPE and 9-HEPE were identified as the effective components among these metabolites, as indicated by their greater suppression of the palmitate-induced expression of inflammatory factors, chemotaxis and JNK activation compared to other metabolites in macrophages. A mixture of 17,18-EEQ, 5-HEPE and 9-HEPE significantly ameliorated the short-term HFD-induced accumulation of macrophages in adipose tissue and hepatic steatosis. CONCLUSION AND IMPLICATIONS: 17,18-EEQ, 5-HEPE and 9-HEPE may be potential approaches to prevent NAFLD in the early stage by inhibiting the inflammatory response in adipose tissue macrophages via JNK signalling.
BACKGROUND AND PURPOSE: The ω-3 polyunsaturated fatty acids (PUFAs) mediate protective effects on several metabolic disorders. However, the functions of their metabolites in the early stage of nonalcoholic fatty liver disease (NAFLD) are largely unknown. EXPERIMENTAL APPROACH: Mice were fed a control diet, high-fat diet (HFD) or ω-3 PUFA-enriched HFD (ω3HFD) for 4 days and phenotypes were analysed. LC-MS/MS was used to determine the eicosanoid profiles. Primary hepatocytes and peritoneal macrophages were used for the mechanism study. KEY RESULTS: In short-term HFD-fed mice, the significantly increased lipid accumulation in the liver was reversed by ω-3 PUFA supplementation. Metabolomics showed that the plasma concentrations of hydroxyeicosapentaenoic acids (HEPEs) and epoxyeicosatetraenoic acids (EEQs) were reduced by a short-term HFD and markedly increased by the ω3HFD. However, HEPE/EEQ treatment had no direct protective effect on hepatocytes. ω3HFD also significantly attenuated HFD-induced adipose tissue inflammation. Furthermore, the expression of pro-inflammatory cytokines and activation of the JNK pathway induced by palmitate were suppressed by HEPEs and EEQs in macrophages. 17,18-EEQ, 5-HEPE and 9-HEPE were identified as the effective components among these metabolites, as indicated by their greater suppression of the palmitate-induced expression of inflammatory factors, chemotaxis and JNK activation compared to other metabolites in macrophages. A mixture of 17,18-EEQ, 5-HEPE and 9-HEPE significantly ameliorated the short-term HFD-induced accumulation of macrophages in adipose tissue and hepatic steatosis. CONCLUSION AND IMPLICATIONS: 17,18-EEQ, 5-HEPE and 9-HEPE may be potential approaches to prevent NAFLD in the early stage by inhibiting the inflammatory response in adipose tissue macrophages via JNK signalling.
Authors: Cristina López-Vicario; José Alcaraz-Quiles; Verónica García-Alonso; Bibiana Rius; Sung H Hwang; Esther Titos; Aritz Lopategi; Bruce D Hammock; Vicente Arroyo; Joan Clària Journal: Proc Natl Acad Sci U S A Date: 2014-12-30 Impact factor: 11.205
Authors: Hilary A Overton; Adam J Babbs; Sheila M Doel; Matthew C T Fyfe; Lisa S Gardner; Graeme Griffin; Helen C Jackson; Martin J Procter; Chrystelle M Rasamison; Mads Tang-Christensen; Peter S Widdowson; Geoffery M Williams; Christine Reynet Journal: Cell Metab Date: 2006-03 Impact factor: 27.287
Authors: Stephen Ph Alexander; Doriano Fabbro; Eamonn Kelly; Neil Marrion; John A Peters; Helen E Benson; Elena Faccenda; Adam J Pawson; Joanna L Sharman; Christopher Southan; Jamie A Davies Journal: Br J Pharmacol Date: 2015-12 Impact factor: 8.739
Authors: Tasnima Siddiquee; Bishwajit Bhowmik; Nayla Cristina Da Vale Moreira; Anindita Mujumder; Hajera Mahtab; A K Azad Khan; Akhtar Hussain Journal: BMC Public Health Date: 2015-09-04 Impact factor: 3.295
Authors: Ana Luisa Gavito; Dolores Bautista; Juan Suarez; Samir Badran; Rocío Arco; Francisco Javier Pavón; Antonia Serrano; Patricia Rivera; Juan Decara; Antonio Luis Cuesta; Fernando Rodríguez-de-Fonseca; Elena Baixeras Journal: PLoS One Date: 2016-06-22 Impact factor: 3.240
Authors: Justin Darcy; Yimin Fang; Samuel McFadden; Matthew D Lynes; Luiz O Leiria; Jonathan M Dreyfuss; Valerie Bussburg; Vladimir Tolstikov; Bennett Greenwood; Niven R Narain; Michael A Kiebish; Andrzej Bartke; Yu-Hua Tseng Journal: Geroscience Date: 2020-07-06 Impact factor: 7.713